Werewolf Therapeutics Inc (NASDAQ:HOWL) — Market Cap & Net Worth
Market Cap & Net Worth: Werewolf Therapeutics Inc (HOWL)
Werewolf Therapeutics Inc (NASDAQ:HOWL) has a market capitalization of $46.80 Million ($46.80 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #22228 globally and #4938 in its home market, demonstrating a -0.21% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Werewolf Therapeutics Inc's stock price $0.96 by its total outstanding shares 48599066 (48.60 Million). Also see Werewolf Therapeutics Inc balance sheet assets for a full breakdown of the balance sheet.
Werewolf Therapeutics Inc Market Cap History: 2021 to 2026
Werewolf Therapeutics Inc's market capitalization history from 2021 to 2026. Data shows change from $578.81 Million to $46.80 Million (-40.72% CAGR). Also see cash flow conversion of Werewolf Therapeutics Inc for how efficiently the company converts equity into cash flow.
Index Memberships
Werewolf Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.00% | #642 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #2114 of 3165 |
Weight: Werewolf Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Werewolf Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Werewolf Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check current stock price of Werewolf Therapeutics Inc for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
38.16x
Werewolf Therapeutics Inc's market cap is 38.16 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $578.81 Million | $4.15 Million | -$49.77 Million | 139.54x | N/A |
| 2022 | $99.63 Million | $16.40 Million | -$51.56 Million | 6.07x | N/A |
| 2023 | $187.59 Million | $19.94 Million | -$37.37 Million | 9.41x | N/A |
| 2024 | $71.93 Million | $1.89 Million | -$70.52 Million | 38.16x | N/A |
Competitor Companies of HOWL by Market Capitalization
Companies near Werewolf Therapeutics Inc in the global market cap rankings as of September 18, 2026. Review HOWL goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Werewolf Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Werewolf Therapeutics Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, Werewolf Therapeutics Inc's market cap moved from $578.81 Million to $ 46.80 Million, with a yearly change of -40.72%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $46.80 Million | +52.01% |
| 2025 | $30.79 Million | -57.20% |
| 2024 | $71.93 Million | -61.66% |
| 2023 | $187.59 Million | +88.29% |
| 2022 | $99.63 Million | -82.79% |
| 2021 | $578.81 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Werewolf Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $46.80 Million USD |
| MoneyControl | $46.80 Million USD |
| MarketWatch | $46.80 Million USD |
| marketcap.company | $46.80 Million USD |
| Reuters | $46.80 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Werewolf Therapeutics Inc
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies throu… Read more